<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01420146</url>
  </required_header>
  <id_info>
    <org_study_id>IJBMNZrT003</org_study_id>
    <nct_id>NCT01420146</nct_id>
  </id_info>
  <brief_title>Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients</brief_title>
  <acronym>IJBMNZrT003</acronym>
  <official_title>Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients : Correlation With FDG-PET/CT and Anatomopathological Results</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jules Bordet Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jules Bordet Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the diagnostic potential of HER2 imaging using zirconium 89 labelled
      trastuzumab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is the first belgian feasibility study of HER2 imaging using a labelled monoclonal
      antibody, namely trastuzumab labelled with zirconium 89.

      The aims of this study are:

      I/ Evaluate the diagnostic potential of HER2 imaging using zirconium 89 labelled trastuzumab
      (based on the Groningen experience), through the analysis of the correlation between the
      FDG-PET/CT and the HER2 immunoPET.

      II/ PET quantification of HER2 receptor by using the images and the blood pharmacokinetic of
      the tracer.

      III/ In the subset of patients for whom biopsies of metastatic sites have not been carried
      out previously and are of an easy access, tissue will be acquired as part of the validation
      of the HER2 immunoPET and as an attempt to better understand the molecular heterogeneity of
      HER2 positive breast cancer at the time of relapse.

      IV/Evaluate the concentration of circulating HER2 extracellular domain in the blood and study
      his possible role as on imaging quality
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Test the Diagnostic Accuracy of the HER2 Imaging Using the Labelled Monoclonal Antibody Trastuzumab by Correlating the HER2 PET/CT Imaging With the FDG-PET/CT and Molecular Characterization of Tumor Samples With Discordant Image Findings</measure>
    <time_frame>4 years</time_frame>
    <description>A visual 'patient-based' classification capturing the whole disease burden was developed by using a side-by-side display, comparing baseline FDG-PET/CT(showing all FDG-positive mets independent of their HER2-imaging status) &amp; day4 HER2-PET/CT. Pts were grouped into 4 HER2-PET/CT patterns according to the proportion of FDG avid tumour load showing relevant 89Zr-T uptake. Pattern A: entire tumor load showed pertinent tracer uptake; B: dominant part of tumour load showed tracer uptake; C: minor part of tumor load showed tracer uptake; D: entire tumor load lacked tracer uptake. Patterns A+B='HER2-positive' &amp; C+D='HER2-negative'. In the 20 pts: 4 pts were classified &quot;A&quot;, 5&quot;B&quot;, 1&quot;C&quot; &amp; 10&quot;D&quot;. This classification indicates substantial heterogeneity of 89Zr-T uptake within this so called 'HER2-positive' pt population. After dichotomization, 11(55%) pts were considered as HER2-PET/CT negative. Furthermore, HER2-PET/CT revealed intrapatient heterogeneity of tumour uptake(pts classified B or C).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time Activity Curve</measure>
    <time_frame>blood sample at 5, 15, 30, 60 minutes, 1 day, 2 days and 4 or 6 days after tracer injection. Images : Day 0, Day 2 and Day 4 or 6</time_frame>
    <description>Time activity curve of normal organ and tumor lesions: pharmacokinetic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HER2 Extracellular Domain</measure>
    <time_frame>within 60 min before tracer injection</time_frame>
    <description>evaluate the concentration of circulating HER2 extracellular domain in the blood and study his possible role as on imaging quality</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Secondary</condition>
  <condition>HER2 Positive Carcinoma of Breast</condition>
  <arm_group>
    <arm_group_label>Zr89-trastuzumab PET/CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zr89-trastuzumab PET/CT single arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zr89-trastuzumab</intervention_name>
    <description>trastuzumab labelled with zirconium 89 for PET/CT</description>
    <arm_group_label>Zr89-trastuzumab PET/CT</arm_group_label>
    <other_name>HER2 ImmunoPET/CT</other_name>
    <other_name>HER2 receptor imaging</other_name>
    <other_name>Breast cancer molecular imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. All patients selected for this imaging study are patients scheduled to start
             trastuzumab-based therapy for advanced HER2 positive breast cancer (This includes
             trastuzumab alone, trastuzumab + chemotherapy, trastuzumab + endocrine therapy).

          2. Histologically confirmed HER 2 positive (defined as FISH amplification ratio more than
             2.2) invasive carcinoma of the breast (primary tumor at diagnosis) with locally
             recurrent or metastatic disease.

          3. Patients with FDG-PET positive metastatic lesions.

          4. Brain metastases are allowed provided they are controlled and they are not the sole
             site of metastatic disease.

          5. Patient planned to have metastatic site biopsy for HER2 status control.

          6. Age ≥ 18 years

          7. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 1

          8. For women of childbearing potential a pregnancy test will be done and an agreement to
             use a highly-effective non hormonal form of contraception.

          9. Agreement from the patient to participate in this imaging study and if indicated
             agreement to biopsy one or two accessible lesions.

         10. Signed written informed consent (approved by the Ethics Committee) obtained prior to
             any study procedure

        Exclusion criteria:

          1. Current severe, uncontrolled systemic disease (e.g., clinically significant
             cardiovascular, pulmonary, or metabolic disease)

          2. Pregnant or lactating women

          3. Current known infection with HIV, HBV, or HCV

          4. Known severe hypersensitivity to trastuzumab

          5. Assessed by the investigator to be unable or unwilling to comply with the requirements
             of the protocol

          6. Patients with bone only metastases are not eligible

          7. Psychiatric illness/social situations that would limit compliance with study
             requirements

          8. Patients who received lapatinib within the 7 days prior to HER immunoPET/CT.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Flamen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jules Bordet Institut</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jules Bordet Institut</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2011</study_first_submitted>
  <study_first_submitted_qc>August 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2011</study_first_posted>
  <results_first_submitted>March 7, 2017</results_first_submitted>
  <results_first_submitted_qc>March 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 18, 2017</results_first_posted>
  <last_update_submitted>March 7, 2017</last_update_submitted>
  <last_update_submitted_qc>March 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Zr89-trastuzumab PET/CT</title>
          <description>Zr89-trastuzumab (trastuzumab labelled with zirconium 89) for PET/CT single arm</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Zr89-trastuzumab PET/CT</title>
          <description>Zr89-trastuzumab (trastuzumab labelled with zirconium 89) for PET/CT single arm</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Test the Diagnostic Accuracy of the HER2 Imaging Using the Labelled Monoclonal Antibody Trastuzumab by Correlating the HER2 PET/CT Imaging With the FDG-PET/CT and Molecular Characterization of Tumor Samples With Discordant Image Findings</title>
        <description>A visual ‘patient-based’ classification capturing the whole disease burden was developed by using a side-by-side display, comparing baseline FDG–PET/CT(showing all FDG-positive mets independent of their HER2-imaging status) &amp; day4 HER2–PET/CT. Pts were grouped into 4 HER2–PET/CT patterns according to the proportion of FDG avid tumour load showing relevant 89Zr-T uptake. Pattern A: entire tumor load showed pertinent tracer uptake; B: dominant part of tumour load showed tracer uptake; C: minor part of tumor load showed tracer uptake; D: entire tumor load lacked tracer uptake. Patterns A+B='HER2-positive’ &amp; C+D=‘HER2-negative’. In the 20 pts: 4 pts were classified “A”, 5“B”, 1“C” &amp; 10“D”. This classification indicates substantial heterogeneity of 89Zr-T uptake within this so called ‘HER2-positive’ pt population. After dichotomization, 11(55%) pts were considered as HER2–PET/CT negative. Furthermore, HER2–PET/CT revealed intrapatient heterogeneity of tumour uptake(pts classified B or C).</description>
        <time_frame>4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zr89-trastuzumab PET/CT</title>
            <description>Zr89-trastuzumab (trastuzumab labelled with zirconium 89) for PET/CT single arm</description>
          </group>
        </group_list>
        <measure>
          <title>Test the Diagnostic Accuracy of the HER2 Imaging Using the Labelled Monoclonal Antibody Trastuzumab by Correlating the HER2 PET/CT Imaging With the FDG-PET/CT and Molecular Characterization of Tumor Samples With Discordant Image Findings</title>
          <description>A visual ‘patient-based’ classification capturing the whole disease burden was developed by using a side-by-side display, comparing baseline FDG–PET/CT(showing all FDG-positive mets independent of their HER2-imaging status) &amp; day4 HER2–PET/CT. Pts were grouped into 4 HER2–PET/CT patterns according to the proportion of FDG avid tumour load showing relevant 89Zr-T uptake. Pattern A: entire tumor load showed pertinent tracer uptake; B: dominant part of tumour load showed tracer uptake; C: minor part of tumor load showed tracer uptake; D: entire tumor load lacked tracer uptake. Patterns A+B='HER2-positive’ &amp; C+D=‘HER2-negative’. In the 20 pts: 4 pts were classified “A”, 5“B”, 1“C” &amp; 10“D”. This classification indicates substantial heterogeneity of 89Zr-T uptake within this so called ‘HER2-positive’ pt population. After dichotomization, 11(55%) pts were considered as HER2–PET/CT negative. Furthermore, HER2–PET/CT revealed intrapatient heterogeneity of tumour uptake(pts classified B or C).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Pattern A</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pattern B</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pattern C</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pattern D</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Activity Curve</title>
        <description>Time activity curve of normal organ and tumor lesions: pharmacokinetic</description>
        <time_frame>blood sample at 5, 15, 30, 60 minutes, 1 day, 2 days and 4 or 6 days after tracer injection. Images : Day 0, Day 2 and Day 4 or 6</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HER2 Extracellular Domain</title>
        <description>evaluate the concentration of circulating HER2 extracellular domain in the blood and study his possible role as on imaging quality</description>
        <time_frame>within 60 min before tracer injection</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Zr89-trastuzumab PET/CT</title>
          <description>Zr89-trastuzumab PET/CT single arm
Zr89-trastuzumab: trastuzumab labelled with zirconium 89 for PET/CT</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea - Pyrexia - Myalgia</sub_title>
                <description>one SAE case containing 3 single events:
Gastrointestinal disorders : Nausea
General disorders and administration site conditions: Pyrexia
Musculoskeletal and connective tissue disorders: Myalgia</description>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Géraldine Gebhart</name_or_title>
      <organization>Institut Jules Bordet</organization>
      <phone>025413095 ext +32</phone>
      <email>geraldine.gebhart@bordet.be</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

